Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor responders have more mutations than good respond...
Guardado en:
Autores principales: | Pascal Gellert, Corrinne V. Segal, Qiong Gao, Elena López-Knowles, Lesley-Ann Martin, Andrew Dodson, Tiandao Li, Christopher A. Miller, Charles Lu, Elaine R. Mardis, Alexa Gillman, James Morden, Manuela Graf, Kally Sidhu, Abigail Evans, Michael Shere, Christopher Holcombe, Stuart A. McIntosh, Nigel Bundred, Anthony Skene, William Maxwell, John Robertson, Judith M. Bliss, Ian Smith, Mitch Dowsett, POETIC Trial Management Group and Trialists |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/555df6a99ecd4105b13f149fab06246c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oestrogen Inhibits Arterial Calcification by Promoting Autophagy
por: Yi-Qun Peng, et al.
Publicado: (2017) -
Insufficient antibody validation challenges oestrogen receptor beta research
por: Sandra Andersson, et al.
Publicado: (2017) -
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
por: Fergus J. Couch, et al.
Publicado: (2016) -
Correction: Corrigendum: Insufficient antibody validation challenges oestrogen receptor beta research
por: Sandra Andersson, et al.
Publicado: (2017) -
Fluorene-9-bisphenol is anti-oestrogenic and may cause adverse pregnancy outcomes in mice
por: Zhaobin Zhang, et al.
Publicado: (2017)